On December 22, Abbott Laboratories received FDA approval for its Volt™ Pulsed Field Ablation (PFA) System, designed to treat atrial fibrillation (AFib). This significant regulatory win is expected to strengthen Abbott's cardiovascular portfolio and expand its access to a fast-growing market, addressing a condition affecting millions. Abbott shares closed up 0.22% at $124.81 on December 24, influenced by a positive market trend for U.S. stock indices, which rose during the shortened trading session, and likely supported by the recent FDA approval.